yingweiwo

Ampicillin [D-(-)-α-Aminobenzylpenicillin)]

Alias: Aminobenzylpenicillin; 69-53-4; Ampicillin; Aminobenzylpenicillin; Ampicillin acid; Tokiocillin; Omnipen; Amcill; Ampicillin Anhydrous; Ampicillin acid; Principen; Amcill;
Cat No.:V5324 Purity: ≥98%
Ampicillin [D-(-)-α-Aminobenzylpenicillin)] is a potent broad-spectrum beta-lactam antibiotic widely used to prevent and treat a number of bacterial infections, such as respiratory tract infections, urinary tract infections, meningitis, salmonellosis, and endocarditis.
Ampicillin [D-(-)-α-Aminobenzylpenicillin)]
Ampicillin [D-(-)-α-Aminobenzylpenicillin)] Chemical Structure CAS No.: 69-53-4
Product category: Bacterial
This product is for research use only, not for human use. We do not sell to patients.
Size Price Stock Qty
1g
2g
5g
10g
25g
Other Sizes

Other Forms of Ampicillin [D-(-)-α-Aminobenzylpenicillin)]:

  • Ampicillin sodium
  • Ampicillin Trihydrate [D-(-)-α-Aminobenzylpenicillin]
  • Ampicillin-d5 (Ampicillin d5)
Official Supplier of:
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Top Publications Citing lnvivochem Products
Product Description

Ampicillin [D-(-)-α-Aminobenzylpenicillin)] is a potent broad-spectrum beta-lactam antibiotic widely used to prevent and treat a number of bacterial infections, such as respiratory tract infections, urinary tract infections, meningitis, salmonellosis, and endocarditis. It may also be used to prevent group B streptococcal infection in newborns. It is used by mouth, by injection into a muscle, or intravenously. Like all antibiotics, it is not useful for the treatment of viral infections.

Biological Activity I Assay Protocols (From Reference)
Targets
β-lactam; cell wall synthesis
ln Vitro
Ampicillin has a dose-dependent effect on swine-derived E. Coli growth inhibition. Ampicillin's effective inhibitory concentration was 2.5 uG/mL[1].
ln Vivo
When hemorrhagic enteritis strikes an 11-week-old pig, ampicillin works wonders to relieve the symptoms[1]. Maximum concentrations of ampicillin are twice as high in bile as they are in serum. After an oral dosage, the peak concentration of ampicillin in portal blood is twice as high as in peripheral blood[2]. Neuroprotection against brain damage caused by ischemia-reperfusion is offered by ampicillin. Ampicillin raises the level of GLT-1 expression while decreasing MMP activity. After global forebrain ischemia, pretreatment with ampicillin dramatically lowers medial hippocampal cell death[3].
Enzyme Assay
SENSITIVITY TESTING[1] A set of 5 replicate tubes at each concentration of the antibiotic were inoculated with one drop each of an 18 hour growth of the test culture. The inoculated tubes were incubated at 37°C. for 6 hours, after which further growth was stopped by mixing formalin at 0.5% final concentration. Growth of cultures was recorded as the optical density, employing a Fisher Electrophotometer3 with a 525 m.u. filter.
Cell Assay
The in vitro susceptibility of 103 cultures of E. coli isolated from scouring and nonscouring pigs, and four cultures of Salmonella isolated from a case of necrotic enteritis was tested against Ampicillin contained in nutrient broth at concentrations of 0, 0.1, 1.0 and 5.0 uG per ml. of the medium. All but three cultures of E. coli were found to be susceptible to 5.0 uG/ml., all Salmonella isolates were also susceptible to this concentration of the antibiotic. Susceptibility of E. coli was also tested by plating dilutions of fecal samples obtained from either a scouring or a nonscouring pig, with E.M.B. agar containing 0, 0.1, 1.0, 2.5, 5.0 and 10.0 uG Ampicillin per ml. of the medium. No difference in the growth of E. coli was observed at 0, 0.1 and 1.0 uG concentrations. The three higher concentrations of the antibiotic inhibited the growth of E. coli proportional to the amount of Ampicillin in each concentration. Ampicillin proved very effective in alleviating the symptoms of hemorrhagic enteritis in a 11-week old pig. The disappearance of scours was associated with the replacement of the previously existing sero-biotypes of fecal E. coliwith another aberrant type of E.coli which produced H2S. No Ampicillin resistant strains of E. coli emerged following treatment of the animal with this antibiotic.[1]
Animal Protocol
Mice: Normal saline is used to dissolve ampicillin. After receiving halothane anesthesia, male C57BL/6 mice had their common carotid arteries blocked bilaterally for 40 minutes. Penicillin G (6,000 U/kg or 20,000 U/kg, intraperitoneally [i.p.]) or ampicillin (200 mg/kg) was given intraperitoneally (i.p.) every day for five days prior to transient forebrain ischemia. The same volume and timing of saline administration were used for the control animals[3].
ADME/Pharmacokinetics
Absorption, Distribution and Excretion
Ampicillin is excreted largely unchanged in the urine.
INTAKE OF FOOD PRIOR TO INGESTION OF AMPICILLIN RESULTS IN LESS COMPLETE ABSORPTION. ... /IT/ APPEARS IN BILE, UNDERGOES ENTEROHEPATIC CIRCULATION & IS EXCRETED IN...FECES. BILIARY CONCN...DEPENDENT ON INTEGRITY OF GALLBLADDER & ITS DUCTS.
Ampicillin is distributed to liver, bile, muscle, kidney, crop, and fat following absorption from the GI or injection site. Ampicillin has been used therapeutically and prophylactically for avian salmonellosis with promising results. ... Ampicillin is excreted in bile.
Anhydrous ampicillin and ampicillin trihydrate are generally stable in the presence of acidic gastric secretions, and 30-55% of an oral dose of the drugs is absorbed from the GI tract in fasting adults. Although peak serum concn may occur as soon as 1 hr after administration, the maximum serum concn is usually attained in approx 2 hr.
Two hr after oral administration of 250 mg of ampicillin in fasting individuals, average peak serum concn of 1.8-2.9 ug/ml are attained. A 500-mg oral dose results in average peak serum concn of 3-6 ug/ml. Concn of the antibiotic in serum are less than 1 ug/ml 6 hr after a 500-mg oral dose.
For more Absorption, Distribution and Excretion (Complete) data for AMPICILLIN (16 total), please visit the HSDB record page.
Metabolism / Metabolites
AMPICILLIN IS DEGRADED BY PENICILLINASE...
YIELDS ALPHA-AMINOBENZYLPENICILLOIC ACID IN BACILLUS, IN PENICILLIUM, AND L-PHENYLGLYCINE IN ESCHERICHIA. /FROM TABLE/
Healthy subjects metabolize about 20% of a given dose (250-500 mg) of ampicillin. Within 12 hr, 7% of the total dose is excreted as metabolites in urine ... Ampicillin is metabolized to 5R,6R-penicilloic acid and 5S,6R-penicilloic acid ... and to piperazine-2,5-dione after oral intake ... Other, unidentified metabolites have been reported ... .
Biological Half-Life
The half-life of all aminopenicillins is approximately 60-90 minutes.
Following ip injection ... the serum half-life /of ampicillin/ was estimated to be 27 min ... .
... /ampicillin's/ plasma half-time is usually 1-2 hr ... but is longer in elderly people ... In patients with renal failure, the half-time was as long as 20 hr ... .
Toxicity/Toxicokinetics
Hepatotoxicity
Rare instances of idiosyncratic liver injury have been reported in persons receiving the aminopenicillins. The incidence is far lower with ampicillin than occurs with amoxicillin, occurring probably in less than 1 in 100,000 exposed persons. Cases are characterized by a short latency period of a few days to as long as two weeks. The onset of liver injury can occur after the antibiotic is stopped. The serum enzyme pattern associated with aminopenicillin liver injury has included a hepatocellular pattern with marked elevations in ALT and AST, and minimal elevations in alkaline phosphatase and rapid recovery after withdrawal. In addition, cholestatic forms of hepatic injury with marked alkaline phosphatase elevations (as also seen with penicillin-induced liver injury) have also been described, some of which have been associated with prolonged cholestasis and, rarely, with vanishing bile duct syndrome. The onset of hepatic injury may be accompanied by skin rash, toxic epidermal necrolysis or Stevens Johnson syndrome. Autoantibodies are uncommon.
Likelihood score: C (probable but rare cause of clinically apparent liver injury).
Effects During Pregnancy and Lactation
◉ Summary of Use during Lactation
Substantial information indicates that ampicillin produces low levels in milk that are not expected to cause adverse effects in breastfed infants. Occasionally disruption of the infant's gastrointestinal flora, resulting in diarrhea or thrush have been reported with penicillins, but these effects have not been adequately evaluated. Ampicillin is acceptable in nursing mothers.
◉ Effects in Breastfed Infants
An uncontrolled observation of the breastfed infants of mothers taking ampicillin noted a seeming increase in cases of diarrhea and candidiasis that was attributed to ampicillin in breastmilk.
In a prospective follow-up study, 5 nursing mothers reported taking ampicillin (dosage unspecified). One mother reported diarrhea in her infant. No rashes or candidiasis were reported among the exposed infants.
A small, controlled, prospective study had mothers monitor their infants for signs of adverse effects (furring of the tongue, feeding difficulties, changes in stool frequency and consistency, diaper rash, and skin rash). Weight change and the development of jaundice were also recorded. No statistical differences in these parameters were found between the infants of the control mothers and those of mothers taking ampicillin.
◉ Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Interactions
...AMPICILLIN...MIXED IN VITRO WITH GENTAMICIN.../FOR PROLONGED PERIODS/ CAUSE LOSS OF GENTAMICIN ANTIMICROBIAL ACTIVITY.
CONCURRENT ADMIN OF PENICILLIN & PROBENECID RESULTS IN HIGHER & MORE SUSTAINED SERUM ANTIBIOTIC LEVELS. /AMPICILLIN HAS BEEN SHOWN TO INTERACT IN SIMILAR MANNER/.
/GENTAMICIN/ RELATED DRUGS...KANAMYCIN, NEOMYCIN & TOBRAMYCIN MAY INTERACT...WITH CARBENICILLIN. /CARBENICILLIN/
LIMITED...DATA INDICATE THAT ASPIRIN, IN LARGE DOSES, INCR SERUM LEVEL & HALF-LIFE OF PENICILLIN WHEN...GIVEN CONCURRENTLY. ALTHOUGH CONCURRENT USE OF HIGH DOSES OF ASPIRIN HAS BEEN SUGGESTED TO INCR CLINICAL BENEFITS OF PENICILLIN, POSSIBLE TOXICITIES DUE TO HIGH-DOSE ASPIRIN ADMIN DISCOURAGE SUCH THERAPY. /PENICILLIN/
For more Interactions (Complete) data for AMPICILLIN (21 total), please visit the HSDB record page.
Non-Human Toxicity Values
LD50 Rat oral 10 g/kg bw
LD50 Mouse oral 15.2 g/kg bw
LD50 Rat ip, 1 day old, 3300 mg/kg bw
LD50 Rat ip, 83 day old, 4500 mg/kg bw
References

[1]. Effect of Ampicillin on E. Coli of Swine Origin. Can J Comp Med Vet Sci. 1963 Sep;27(9):223-7.

[2]. Ampicillin in portal and peripheral blood and bile after oral administration of ampicillin andpivampicillin. Eur J Clin Pharmacol. 1974;7(2):133-5.

[3]. The neuroprotective mechanism of ampicillin in a mouse model of transient forebrain ischemia. Korean J Physiol Pharmacol. 2016 Mar;20(2):185-92.

Additional Infomation
Ampicillin is a penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-phenylacetamido group. It has a role as an antibacterial drug. It is a penicillin, a penicillin allergen and a beta-lactam antibiotic. It is a conjugate acid of an ampicillin(1-).
Ampicillin is a semi-synthetic derivative of penicillin that functions as an orally active broad-spectrum antibiotic.
Ampicillin is a Penicillin-class Antibacterial.
Ampicillin has been reported in Microsphaeropsis arundinis, Aspergillus banksianus, and other organisms with data available.
Ampicillin is a broad-spectrum, semi-synthetic, beta-lactam penicillin antibiotic with bactericidal activity. Ampicillin binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This interrupts bacterial cell wall synthesis and results in the weakening of the bacterial cell wall and causes cell lysis. Ampicillin is stable against hydrolysis by a variety of beta-lactamases, therefore, can be used in wide range of gram-positive and -negative infections.
Semi-synthetic derivative of penicillin that functions as an orally active broad-spectrum antibiotic.
Drug Indication
For treatment of infection (Respiratory, GI, UTI and meningitis) due to E. coli, P. mirabilis, enterococci, Shigella, S. typhosa and other Salmonella, nonpenicillinase-producing N. gononhoeae, H. influenzae, staphylococci, streptococci including streptoc
Mechanism of Action
By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, Ampicillin inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that Ampicillin interferes with an autolysin inhibitor.
SINCE PENICILLIN HAS NO EFFECT ON EXISTING CELL WALLS, BACTERIA MUST BE MULTIPLYING FOR BACTERICIDAL ACTION OF PENICILLIN TO BE MANIFEST. /PENICILLINS/
The penicillins and their metabolites are potent immunogens because of their ability to combine with proteins and act as haptens for acute antibody-mediated reactions. The most frequent (about 95 percent) or "major" determinant of penicillin allergy is the penicilloyl determinant produced by opening the beta-lactam ring of the penicillin. This allows linkage of the penicillin to protein at the amide group. "Minor" determinants (less frequent) are the other metabolites formed, including native penicillin and penicilloic acids. /Penicillins/
Bactericidal; inhibit bacterial cell wall synthesis. Action is dependent on the ability of penicillins to reach and bind penicillin binding proteins located on the inner membrane of the bacterial cell wall. Penicillin binding proteins (which include transpeptidases, carboxypeptidases, and endopeptidases) are enzymes that are involved in the terminal stages of assembling the bacterial cell wall and in reshaping the cell wall during growth and division. Penicillins bind to, and inactivate, penicillin binding proteins, resulting in the weakening of the bacterial cell wall and lysis. /Penicillins/
Therapeutic Uses
Penicillins
FOR MILD TO MODERATELY SEVERE DISEASE, ORAL...ADULTS...1-4 G/DAY, DIVIDED INTO EQUAL PORTIONS...EVERY 6 HR. FOR SEVERE INFECTIONS...BEST TO ADMIN... PARENTERALLY...6-12 G/DAY. ...MENINGITIS REQUIRES...300-400 MG/KG/DAY PARENTERALLY (IN EQUALLY DIVIDED PORTIONS...EVERY 4 HR) FOR CHILDREN, & 12 G OR MORE/DAY FOR ADULTS.
DOSE VARIES WITH TYPE & SEVERITY OF INFECTION...RENAL FUNCTION &...AGE. FOR CHILDREN.../NOT/ ON BASIS OF BODY WT OR SURFACE AREA; BECAUSE DRUG...EXCRETED MAINLY BY KIDNEY ...RENAL FUNCTION TO GREAT EXTENT DETERMINES DOSE. VERY YOUNG BABIES...REQUIRE SMALL DOSES ...CHILDREN 3-4 YR.../DOSE/ ALMOST AS LARGE AS...ADULTS.
Ampicillin /is/ indicated in the treatment of acute otitis media caused by susceptible organisms. /Included in US product labeling/
For more Therapeutic Uses (Complete) data for AMPICILLIN (18 total), please visit the HSDB record page.
Drug Warnings
IN 1 INSTANCE, FATAL PSEUDOMEMBRANOUS COLITIS OCCURRED FOLLOWING 5 DAYS OF ORAL AMPICILLIN THERAPY IN DOSAGE OF 2 G DAILY. VERY RARELY, AMPICILLIN HAS PRODUCED INTERSTITIAL NEPHRITIS; 1 CASE OF INTERSTITIAL NEPHRITIS REPORTEDLY PROGRESSED TO ACUTE RENAL FAILURE. ...CRYSTALLURIA HAS BEEN REPORTED...
PERIODIC ASSESSMENT OF RENAL, HEPATIC & HEMATOPOIETIC FUNCTION SHOULD BE CONDUCTED DURING PROLONGED THERAPY, ESP IN PREMATURE, NEWBORN & OTHER INFANTS.
ABSORPTION EFFICIENCY & RATE OF ELIMINATION OF AMPICILLIN...DECR IN PT WITH SHIGELLOSIS. POOR ABSORPTION...GENERALLY OBSERVED IN YOUNGER PATIENTS WITH MARKED DIARRHEA. ... DELAYED EXCRETION. MARKED RETENTION...IN PLASMA...NOTED IN PT WITH RENAL FAILURE.
NATIONAL REGISTRY OF POSSIBLE DRUG INDUCED OCULAR SIDE EFFECTS ESTABLISHED IN 1975 BY FDA IN ORDER TO MAKE PHYSICIANS AWARE THAT SOME DRUGS SUCH AS AMPICILLIN MAY CAUSE SIDE EFFECTS TO EYE IS DISCUSSED.
For more Drug Warnings (Complete) data for AMPICILLIN (16 total), please visit the HSDB record page.
Pharmacodynamics
Ampicillin is a penicillin beta-lactam antibiotic used in the treatment of bacterial infections caused by susceptible, usually gram-positive, organisms. The name "penicillin" can either refer to several variants of penicillin available, or to the group of antibiotics derived from the penicillins. Ampicillin has in vitro activity against gram-positive and gram-negative aerobic and anaerobic bacteria. The bactericidal activity of Ampicillin results from the inhibition of cell wall synthesis and is mediated through Ampicillin binding to penicillin binding proteins (PBPs). Ampicillin is stable against hydrolysis by a variety of beta-lactamases, including penicillinases, and cephalosporinases and extended spectrum beta-lactamases.
These protocols are for reference only. InvivoChem does not independently validate these methods.
Physicochemical Properties
Molecular Formula
C16H19N3O4S
Molecular Weight
349.40476
Exact Mass
349.109
Elemental Analysis
C, 55.00; H, 5.48; N, 12.03; O, 18.32; S, 9.18
CAS #
69-53-4
Related CAS #
Ampicillin sodium;69-52-3;Ampicillin trihydrate;7177-48-2;Ampicillin-d5;1426173-65-0; Ampicillin;69-53-4;Ampicillin trihydrate;7177-48-2; 69-53-4 (free acid); 23277-71-6 (potassium); 114977-84-3 (trimer trisodium) ; 69-52-3 (sodium); 7490-86-0 (hemisulfate); 33276-75-4 (benzathine); 119229-01-5 (embonate); 40688-84-4 (HCl)
PubChem CID
6249
Appearance
White to off-white solid powder
Density
1.6±0.1 g/cm3
Boiling Point
644.5±65.0 °C at 760 mmHg
Melting Point
198-200 °C (dec.)(lit.)
Flash Point
343.6±34.3 °C
Vapour Pressure
0.0±2.0 mmHg at 25°C
Index of Refraction
1.724
LogP
1.65
Hydrogen Bond Donor Count
3
Hydrogen Bond Acceptor Count
6
Rotatable Bond Count
4
Heavy Atom Count
24
Complexity
562
Defined Atom Stereocenter Count
4
SMILES
OC([C@@H]1N(C2=O)[C@]([C@@H]2NC([C@@H](C3=CC=CC=C3)N)=O)([H])SC1(C)C)=O
InChi Key
AVKUERGKIZMTKX-UHFFFAOYSA-N
InChi Code
InChI=1S/C16H19N3O4S/c1-16(2)11(15(22)23)19-13(21)10(14(19)24-16)18-12(20)9(17)8-6-4-3-5-7-8/h3-7,9-11,14H,17H2,1-2H3,(H,18,20)(H,22,23)
Chemical Name
(2S,5R,6R)-6-[[(2R)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
Synonyms
Aminobenzylpenicillin; 69-53-4; Ampicillin; Aminobenzylpenicillin; Ampicillin acid; Tokiocillin; Omnipen; Amcill; Ampicillin Anhydrous; Ampicillin acid; Principen; Amcill;
HS Tariff Code
2934.99.9001
Storage

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Note: This product requires protection from light (avoid light exposure) during transportation and storage.
Shipping Condition
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
Solubility Data
Solubility (In Vitro)
0.1 M NaOH : ~25 mg/mL (~71.55 mM)
H2O : ~4.9 mg/mL (~14.02 mM)
Solubility (In Vivo)
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.

Injection Formulations
(e.g. IP/IV/IM/SC)
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution 50 μL Tween 80 850 μL Saline)
*Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution.
Injection Formulation 2: DMSO : PEG300Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO 400 μLPEG300 50 μL Tween 80 450 μL Saline)
Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO 900 μL Corn oil)
Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals).
View More

Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO 900 μL (20% SBE-β-CD in saline)]
*Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.
Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin 500 μL Saline)
Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO 100 μLPEG300 200 μL castor oil 650 μL Saline)
Injection Formulation 7: Ethanol : Cremophor : Saline = 10: 10 : 80 (i.e. 100 μL Ethanol 100 μL Cremophor 800 μL Saline)
Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline
Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH 900 μL Corn oil)
Injection Formulation 10: EtOH : PEG300Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH 400 μLPEG300 50 μL Tween 80 450 μL Saline)


Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium)
Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose
Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals).
View More

Oral Formulation 3: Dissolved in PEG400
Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose
Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose
Oral Formulation 6: Mixing with food powders


Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently.

 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 2.8620 mL 14.3102 mL 28.6205 mL
5 mM 0.5724 mL 2.8620 mL 5.7241 mL
10 mM 0.2862 mL 1.4310 mL 2.8620 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.

Calculator

Molarity Calculator allows you to calculate the mass, volume, and/or concentration required for a solution, as detailed below:

  • Calculate the Mass of a compound required to prepare a solution of known volume and concentration
  • Calculate the Volume of solution required to dissolve a compound of known mass to a desired concentration
  • Calculate the Concentration of a solution resulting from a known mass of compound in a specific volume
An example of molarity calculation using the molarity calculator is shown below:
What is the mass of compound required to make a 10 mM stock solution in 5 ml of DMSO given that the molecular weight of the compound is 350.26 g/mol?
  • Enter 350.26 in the Molecular Weight (MW) box
  • Enter 10 in the Concentration box and choose the correct unit (mM)
  • Enter 5 in the Volume box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 17.513 mg appears in the Mass box. In a similar way, you may calculate the volume and concentration.

Dilution Calculator allows you to calculate how to dilute a stock solution of known concentrations. For example, you may Enter C1, C2 & V2 to calculate V1, as detailed below:

What volume of a given 10 mM stock solution is required to make 25 ml of a 25 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=25 μM, V2=25 ml and V1 is the unknown:
  • Enter 10 into the Concentration (Start) box and choose the correct unit (mM)
  • Enter 25 into the Concentration (End) box and select the correct unit (mM)
  • Enter 25 into the Volume (End) box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 62.5 μL (0.1 ml) appears in the Volume (Start) box
g/mol

Molecular Weight Calculator allows you to calculate the molar mass and elemental composition of a compound, as detailed below:

Note: Chemical formula is case sensitive: C12H18N3O4  c12h18n3o4
Instructions to calculate molar mass (molecular weight) of a chemical compound:
  • To calculate molar mass of a chemical compound, please enter the chemical/molecular formula and click the “Calculate’ button.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
  • Molecular mass (or molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
  • Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
/

Reconstitution Calculator allows you to calculate the volume of solvent required to reconstitute your vial.

  • Enter the mass of the reagent and the desired reconstitution concentration as well as the correct units
  • Click the “Calculate” button
  • The answer appears in the Volume (to add to vial) box
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal to make allowance for loss during the experiment)
Step 2: Enter in vivo formulation (This is only a calculator, not the exact formulation for a specific product. Please contact us first if there is no in vivo formulation in the solubility section.)
+
+
+

Calculation results

Working concentration mg/mL;

Method for preparing DMSO stock solution mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.

Method for preparing in vivo formulation:Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.

(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
             (2) Be sure to add the solvent(s) in order.

Clinical Trial Information
Short Versus Standard of Care Antibiotic Duration for Children Hospitalized for CAP
CTID: NCT06494072
Phase: Phase 4    Status: Recruiting
Date: 2024-11-20
Prophylactic Effects for Preventing Surgical Site Infection in Third Molar Surgery
CTID: NCT06368102
Phase: Phase 4    Status: Recruiting
Date: 2024-08-07
A Study to Compare Different Antibiotics and Different Modes of Fluid Treatment for Children With Severe Pneumonia
CTID: NCT04041791
Phase: Phase 3    Status: Completed
Date: 2024-07-08
Treatment of ppROM With Erythromycin vs. Azithromycin Trial
CTID: NCT03060473
Phase: Phase 3    Status: Terminated
Date: 2024-06-25
Azithromycin for Preterm Pre-labor Rupture of Membranes
CTID: NCT04202380
Phase: N/A    Status: Completed
Date: 2024-04-24
View More

NICU Antibiotics and Outcomes Trial
CTID: NCT03997266
Phase: Phase 4    Status: Recruiting
Date: 2024-01-17


NICU Antibiotics and Outcomes (NANO) Follow-up Study
CTID: NCT05977400
Phase: Phase 3    Status: Not yet recruiting
Date: 2023-08-04
Strategies to Reduce Mortality Among HIV-infected and HIV-exposed Children Admitted With Severe Acute Malnutrition
CTID: NCT05051163
Phase: Phase 2/Phase 3    Status: Unknown status
Date: 2021-09-30
A Randomized Controlled Trial Investigating if Antibiotic Use in the First 48 Hours of Life Adversely Impacts the Preterm Infant Microbiome
CTID: NCT02477423
Phase: N/A    Status: Completed
Date: 2020-10-08
Endourology Disease Group Excellence (EDGE) Consortium: Antibiotics (Abx) for Percutaneous Nephrolithotomy (PCNL) Part 2
CTID: NCT02829060
Phase: N/A    Status: Recruiting
Date: 2020-03-24
A Randomized Trial of Preoperative Prophylactic Antibiotics Prior to Kidney Stone Surgery (Percutaneous Nephrolithotomy [PCNL])
CTID: NCT02384200
Phase: Phase 4    Status: Completed
Date: 2019-08-22
Successful Treatment of Maternal Listeria Monocytogenes Bacteremia in the First Trimester
CTID: NCT03248973
Phase:    Status: Completed
Date: 2019-02-12
Safety, Tolerability and Efficacy of Ceftaroline in Paediatrics With Late-Onset Sepsis
CTID: NCT02424734
Phase: Phase 2    Status: Terminated
Date: 2018-09-13
Ampicillin for DYT-1 Dystonia Motor Symptoms
CTID: NCT01433757
Phase: Phase 1    Status: Completed
Date: 2017-07-05
Pharmacokinetic (PK) and Pharmacodynamic (PD) Modeling of Ampicillin and Gentamicin in Peripartum Patients
CTID: NCT02427932
Phase:    Status: Completed
Date: 2017-05-10
Antibiotic Prophylaxis in Prelabor Rupture of Membranes at Term
CTID: NCT01633294
Phase: Phase 2/Phase 3    Status: Completed
Date: 2016-11-28
Efficacy, Pharmacokinetics and Safety of Meropenem in Infants Below 90 Days With Clinical or Confirmed Late-onset Sepsis
CTID: NCT01551394
Phase: Phase 3    Status: Completed
Date: 2015-02-16
Prophylactic Antibiotics for Manual Removal of Retained Placenta in Vaginal Birth: a Randomized Controlled Trial
CTID: NCT01945450
Phase: N/A    Status: Unknown status
Date: 2013-11-27
Antimicrobial PK in Infants With Suspected or Confirmed Infection
CTID: NCT00491426
Phase:    Status: Completed
D
Shortened Antibiotic Treatment in Community-Acquired Pneumonia: A Nationwide Danish Randomized Controlled Trial
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2019-04-29
Effects of antibiotics on micobiota, pulmonary immune response and incidence of ventilator-associated infections
CTID: null
Phase: Phase 4    Status: Prematurely Ended
Date: 2019-01-14
Pharmacokinetics of antibiotics in cerebrospinal fluid of children with external ventricular drain
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2018-09-27
Therapeutic drug monitoring and continuous infusion of beta-lactam antibiotics in patients with bacteraemia.
CTID: null
Phase: Phase 4    Status: Prematurely Ended
Date: 2017-06-27
Randomized, multicenter, open, phase III, controlled clinical trial, to demonstrate the non-inferiority of reduced antibiotic treatment directed against the treatment of a broad spectrum betalactam antipseudomonal in treating patients with bacteremia spectrum Enterobacteriaceae
CTID: null
Phase: Phase 3    Status: Completed
Date: 2016-03-18
Multiple-dose pharmacokinetics of ampicillin / sulbactam and amoxicillin / clavulanic acid during haemodialysis in longterm haemodialysis patients
CTID: null
Phase: Phase 4    Status: Completed
Date: 2013-07-19
Neonatal and Paediatric Pharmacokinetics of Antimicrobials study
CTID: null
Phase: Phase 4    Status: GB - no longer in EU/EEA
Date: 2013-07-19
Pharmacokinetics of penicillin, ampicillin and gentamicin in near- term and full-term neonates
CTID: null
Phase: Phase 4    Status: Completed
Date: 2012-12-20
Pre-emptive targeted and optimized treatment of critical airway colonization to prevent Ventilator Associated Pneumonia: a randomized controlled study
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2012-08-22
Individualizing duration of antibiotic therapy in hospitalized patients with community-acquired pneumonia: a non-inferiority, randomized, controlled trial.
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2011-12-20
Estudio de la eficacia de la administración prolongada de antibióticos betalactámicos frente a la administración intermitente en el tratamiento de la infección causada por microorganismo sensibles pero con concentraciones mínimas inhibitorias altas
CTID: null
Phase: Phase 4    Status: Prematurely Ended
Date: 2011-10-27
EFFICACY, PHARMACOKINETICS AND SAFETY OF MEROPENEM IN INFANTS BELOW 90 DAYS OF AGE (INCLUSIVE) WITH CLINICAL OR CONFIRMED LATE-ONSET SEPSIS: A EUROPEAN MULTICENTER RANDOMISED PHASE III TRIAL
CTID: null
Phase: Phase 3    Status: Completed
Date: 2011-08-25
A prospective, double-blind, multi center, randomized clinical study to compare the efficacy and safety of Ertapenem 3 days versus Ampicillin- Sulbactam 3 days in the treatment of localized community acquired intra-abdominal infection (IAI).
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2007-09-25
Clinical and economical efficiency and safety and inflammation parameter correlations study of concervative treatment of non-complicated acute appendicitis in 7 to 18 years old children.
CTID: null
Phase: Phase 4    Status: Ongoing
Date:

Biological Data
  • Effect of the ampicillin pretreatment (200 mg/kg for 5 days) on delayed neuronal death in the hippocampus of mice after transient global forebrain ischemia. (A) Representative images of cresyl violet-stained brain coronal sections 3 days after transient forebrain ischemia or sham manipulation. Daily treatment with ampicillin protected the medial CA1 pyramidal cells of the hippocampus 3 days after forebrain ischemia. The scale bars in e and f indicate 200 µm and 20 µm, respectively. (B) Quantitative analysis of the neuronal damage in the saline- and ampicillin-treated groups. *p<0.05.[3]. The neuroprotective mechanism of ampicillin in a mouse model of transient forebrain ischemia. Korean J Physiol Pharmacol. 2016 Mar;20(2):185-92.
  • Effect of the penicillin G sodium salt pretreatment (6,000, 20,000 U/kg, for 5 days) on delayed hippocampal neuronal death after transient global forebrain ischemia in mice. (A) Representative images of cresyl violet-stained brain coronal sections 3 days after transient forebrain ischemia or sham manipulation. The penicillin G sodium salt did not protect the medial CA1 pyramidal cells of the hippocampus 3 days after ischemia/reperfusion. The scale bars in e and f indicate 200 µm and 20 µm, respectively. (B) Quantitative analysis of the neuronal damage in the saline- and ampicillin-treated groups. There was no significant difference in neuronal damage between the saline- and penicillin G-treated groups.[3]. The neuroprotective mechanism of ampicillin in a mouse model of transient forebrain ischemia. Korean J Physiol Pharmacol. 2016 Mar;20(2):185-92.
  • Expression level of the GLT-1 protein in the hippocampus. (A) Representative image of a western blot from the control and ampicillin-treated mice. In this study, normal mice were intraperitoneally administered ampicillin or saline for 5 days. (B) Quantitative data of GLT-1 expression in the hippocampus. The data are presented as the mean±SEM. *p<0.05.[3]. The neuroprotective mechanism of ampicillin in a mouse model of transient forebrain ischemia. Korean J Physiol Pharmacol. 2016 Mar;20(2):185-92.
Contact Us